Antiviral effect of a Qingwen Jiedu formula on the influenza A virus FM1 strain in mice / 国际药学研究杂志

Objective To investigate the antiviral effect of a Qingwen Jiedu formula(QJF)on the influenza A virus FM1 strain using the virus-infected mouse model.Method BALB/c mice were randomly divided into the normal control group(to adminis-ter the same volume of saline),model control group(to administer the same volume of saline),positive drug control group[to admin-ister the 10 mg/(kg·d)of oseltamivir phosphate],and the 5,10 and 20 g/(kg·d)QJF-test groups,respectively.The mice in the nor-mal control group were intranasally instilled with PBS 20 μl,while the others were infected with the equal volume of diluted influenza virus solutions via the same intranasal way.After two hours of the virus infection,the drugs or saline solutions were orally administered to the mice once a day for successive six days.The mortality,average of survival time and protection rate on the animal death were de-termined to evaluate the protective effect of QJF on the virus-infected mice.Furthermore,the lung index,lung tissue viral load and se-rum levels of the inflammatory factors,TNF-α,IFN-γ,IL-6,were also detected as the related indicators for the effect of QJF. Re-sults Compared with the model control group,the mortality of the mice was significantly decreased together with the significant im-provement of the average survival time and protection rate in the 5,10 and 20 g/(kg·d)QJF groups(P<0.01).Further in the10 and 20 g/(kg·d)QJF groups,the lung index and lung tissue viral load decreased significantly both at the third day and sixth day of the vi-rus infection(P<0.01).Meanwhile,the serum IL-6 and TNF-α levels were also significantly decreased(P<0.01),while the serum IFN-γ levels increased significantly in the 10 and 20 g/(kg·d)QJF groups(P<0.01)than in the model control group,especially with a more significant increase in the 10 g/(kg·d)QJF group.Conclusion QJF showed an antiviral effect on the influenza A virus FM1 strain in the in vivo test in mice,which was thus expected likely to be developed as a new anti-influenza drug in future.

c-SRC knockdown decreases phosphorylated STAT3 expression and viability of HeLa cells / 生理学报

The present study was to determine the effect of c-SRC on the viability of human cervical cancer HeLa cells and the expression of phosphorylated signal transducer and activator of transcription-3 (p-STAT3) of the cell. Post-transfection of c-SRC RNA interference vector, RT-PCR and Western blot were utilized to observe the contents of c-SRC mRNA and protein, respectively, in HeLa cells. The MTT was used to observe the viability of the cells. Cell cycle was observed by flow cytometry. The content of p-STAT3 in the cells was also investigated after knockdown of c-SRC. Knockdown of c-SRC significantly decreased the contents of c-SRC mRNA and protein in the cells. The viability of the cells decreased by 23.1%, 29.3%, 38.6% and 45.0% (all P < 0.05), respectively, after the cells were transfected with c-SRC RNA interference vector for 24, 48, 72, and 96 h. The number of S-phase cells decreased by 5.6%, 10.0%, 15.2% and 19.9% (all P < 0.05), respectively, after transfection of c-SRC RNA interference vector for 24, 48, 72, and 96 h. The content of p-STAT3 also decreased when c-SRC was knockdowned. Compared with the control group, after treatment of HeLa cells with STAT3 inhibitor Piceatannol for 24, 48, 72, and 96 h, the cell viability decreased by 23.8%, 29.7%, 37.3% and 45.4% (all P < 0.05), respectively, while increase of c-SRC content could not reverse the inhibitory effect. These results suggest that the inhibited viability of HeLa cells caused by knockdown of c-SRC is associated with the decreased content of p-STAT3 protein.

Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study / 中华病理学杂志

<p><b>OBJECTIVE</b>To investigate the expression of HER2/neu, Ki-67 and TK1 protein in meningiomas in correlation with tumor grades and recurrence.</p><p><b>METHODS</b>Twenty cases of each of the following types of meningiomas were selected for the study, namely: the benign non-recurrent, recurrent benign, atypical and malignant, according to the World Health Organization (WHO) histological classification of nervous system, 2007. Immunohistochemistry study for HER2/neu, Ki-67 and TK1 protein was performed. HER2/neu gene amplification was detected using FISH. Cases with HER2 protein overexpression were studied by immunohistochemistry staining. The results of the biomarker assays were also used to study the correlationship with the tumor grades and tumor recurrency.</p><p><b>RESULTS</b>Immunohistochemistry showed that the positive rates of HER2 expression in non-recurrence benign group, recurrence benign group, atypical group and malignant group were 3 cases (15%), 6 cases (30%), 7 cases (35%), and 10 cases (50%), respectively (P < 0.05). A higher tumor grade was correlated with a higher rate of HER2/neu expression. The Ki-67 and TK1 labeling index (LI) in non-recurrence group were lower than those in the atypical or malignant group (P < 0.05), whereas the atypical group had lower LI than that of the malignant group (P < 0.05). Higher levels of LI of Ki-67 and TK1 were correlated with higher tumor grades and recurrence of the benign meningiomas (P < 0.05). Expression of HER2 was positively correlated with Ki-67 and TK1 (r = 0.445, P < 0.01; r = 0.501, P < 0.01, respectively), and there was a positive correlation between Ki-67 and TK1 (r = 0.450, P < 0.01) as well. HER2/neu gene copy amplification in 7 of 26 cases (26.9%) of HER2 immunopositive meningiomas. The rates of HER2/neu gene amplification were 0 in tumors with 1+ immunopositivity, 4/6 in tumor with 2+ immunopositivity and 3/4 in tumor with 3+ immunopositivity. HER2/neu gene amplification in 3+ and 2+ immunopositive cases had no statistical significance (P > 0.05). Aneuploidy of chromosome 17 existed in 9 of 26 of HER2 immunopositive meningiomas (34.6%). However, the rates of chromosome 17 aneuploidy had no significant difference among tumors with variable HER2/neu imumopositivity (P > 0.05).</p><p><b>CONCLUSIONS</b>High levels of HER2 and Ki-67 or TK1 expression correlate with the increase of tumor grades and tumor recurrence. HER2/neu gene amplification is seen in a subset of meningiomas with the protein expression (26.9%). A combination of biomarker study including HER2/neu, Ki-67 and TK1 may be useful in predicting the biological behavior of meningiomas.</p>